Oxygenta Pharmaceutical Ltd. - Research Center

---

Results

• Quarterly
• Half yearly
• Annual

Statement

• Balance sheet
• P&L
• Cash flow

More

• Share holding
• Capital structures
• Ratio

Mar ' 23	Mar ' 22	Mar ' 21	Mar ' 20	Mar ' 19

Sources of funds

Owner's fund

Equity share capital

14.20

14.20

10.20

10.20

10.20

Share application money

-

-

-

-

-

Preference share capital

-

-

-

-

-

Reserves & surplus

-60.40

-48.83

-48.22

-51.15

-45.36

Loan funds

Secured loans

67.99

52.13

2.85

1.00

0.99

Unsecured loans

-

-

45.04

24.94

20.37

Total

21.79

17.50

9.87

-15.01

-13.80

Uses of funds

Fixed assets

Gross block

46.43

36.44

31.18

25.10

24.58

Less : revaluation reserve

-

-

-

-

-

Less : accumulated depreciation

18.52

16.46

14.87

13.68

12.68

Net block

27.91

19.98

16.31

11.42

11.90

Capital work-in-progress

-

0.34

0.65

-

-

Investments

0.05

0.05

0.05

0.05

0.05

Net current assets

Current assets, loans & advances

26.30

10.81

16.85

7.15

9.21

Less : current liabilities & provisions

32.47

13.68

24.00

33.63

34.96

Total net current assets

-6.17

-2.87

-7.15

-26.48

-25.75

Miscellaneous expenses not written

-

-

-

-

-

Total

21.79

17.50

9.87

-15.01

-13.80

Notes:

Book value of unquoted investments

0.05

0.05

-

-

-

Market value of quoted investments

-

-

-

-

-

Contingent liabilities

-

1.20

1.20

1.20

1.20

Number of equity sharesoutstanding (Lacs)

142.01

142.01

102.01

102.01

102.01